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Background: Thrombocytopenia is a common finding in adults with severe falciparum malaria, but its clinical and
prognostic utility is incompletely defined.
Methods: Clinical and laboratory data from 647 adults with severe falciparum malaria were analysed retrospectively
to determine the relationship between a patient’s platelet count on admission to hospital and their subsequent
clinical course.
Results: On admission, 614 patients (94.9%) were thrombocytopenic (platelet count <150 × 109/L) and 328 (50.7%)
had a platelet count <50 × 109/L. The admission platelet count was inversely correlated with parasite biomass
(estimated from plasma PfHRP2 concentrations, rs = −0.28, P = 0.003), the degree of microvascular sequestration
(measured with orthogonal polarizing spectral imaging, rs = −0.31, P = 0.001) and disease severity (the number of
World Health Organization severity criteria satisfied by the patient, rs = −0.21, P <0.001). Platelet counts were lower
on admission in the patients who died (median: 30 (interquartile range 22 to 52) × 109/L versus 50 (34 to 78) × 109/L in
survivors; P <0.001), but did not predict outcome independently from other established laboratory and clinical
prognostic indices. The 39 patients (6%) with profound thrombocytopenia (platelet count <20 × 109/L) were more
likely to die (odds ratio: 5.00, 95% confidence interval: 2.56 to 9.75) than patients with higher platelet counts, but
these high-risk patients could be identified more rapidly with simple bedside clinical assessment. The admission
platelet count did not reliably identify the 50 patients (7.7%) with major bleeding during the study.
Conclusions: Thrombocytopenia is a marker of disease severity in adults with falciparum malaria, but has limited
utility in prognostication, triage and management.
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Thrombocytopenia is an early and consistent feature of
malaria [1-4], but its pathogenesis remains incompletely
understood. In falciparum malaria there is increased
platelet consumption as evidenced by shortened survival
of radiolabelled platelets [5] and the finding of plenti-
ful megakaryocytes in patients’ bone marrow [6] and* Correspondence: drjoshhanson@gmail.com
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unless otherwise stated.appropriately elevated plasma thrombopoietin levels
[7]. Both systemic microvascular sequestration [8] and
endothelial activation [9,10] may play a pathophysio-
logical role, a hypothesis supported by the observation
that the radiolabelled platelets of patients with falciparum
malaria are diffusely sequestered, rather than pooling in
the liver or spleen [5]. Yet while thrombocytopenia is a
ubiquitous laboratory finding, it had been thought to have
limited clinical significance, as major bleeding is relatively
uncommon in the disease [11].
Recently it has been suggested that thrombocytopenia
may have important implications for patient triage.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Calculation of the RCAM score
Score
Variable 0 (Normal) 1 (Abnormal) 2 (Very abnormal)
Glasgow coma scale 15 11 to 14 ≤10
Respiratory rate <20 20 to 39 ≥40
RCAM (0 to 4) is calculated as the respiratory rate score (0 to 2) plus the GCS
score (0 to 2).
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thrombocytopenia and outcome [12] and a recent study
from India proposed that thrombocytopenia should be
added to the World Health Organization (WHO) cri-
teria for the definition of severe malaria [13]. To clarify
this issue, data from adults with severe falciparum malaria
prospectively enrolled in clinical studies of severe malaria
were analysed to determine if the platelet count could as-
sist in clinical decision-making and whether the degree of
thrombocytopenia has predictive utility independent of
current clinical and laboratory prognostic indices. Measures
of microvascular sequestration and endothelial activation
and their relationship with the platelet count were exam-
ined to further explore the pathogenesis of the thrombo-
cytopaenia seen in the disease.
Methods
Two datasets were combined for this analysis. The first
(n = 560) was compiled prospectively at the Centre for
Tropical Diseases in Ho Chi Minh City, Vietnam, between
1991 and 1996 in a study that compared the efficacy of
artemether and quinine in adults with severe falciparum
malaria [14]. The second comprised data collected pro-
spectively in studies assessing a range of adjunctive ther-
apies in severe falciparum malaria at Chittagong Medical
College Hospital, Bangladesh, and Ispat General Hospital,
Rourkela, India, between 2004 and 2011 [15-18].
Malaria transmission was low and seasonal at all sites.
Falciparum malaria was diagnosed if a blood film showed
asexual forms of Plasmodium falciparum. When expert mi-
croscopy was not available immediately, patients were en-
rolled if an immunochromatographic rapid diagnostic test
(Paracheck Pf, Orchid Biomedical Systems, Goa, India) was
positive; P. falciparum infection was confirmed later by
microscopy of a simultaneously collected blood slide.
All patients satisfied a strict definition of severe fal-
ciparum malaria that used modified WHO criteria
[19], including cerebral malaria (Glasgow Coma Scale
(GCS) <11); severe anaemia (haematocrit <20% with a para-
site count > l00,000/mm3); renal failure (blood urea nitro-
gen ≥21.4 mmol/L or plasma creatinine level ≥265 μmol/L);
pulmonary oedema (oxygen saturation <90% and bibasal
crepitations); generalized convulsions; acidosis (ven-
ous bicarbonate <15 mmol/L); hyperparasitaemia (per-
ipheral parasitaemia >10%); hyperlactataemia (venous
lactate >4 mmol/L); jaundice (bilirubin >43 μmol/L
and a parasite count > l00,000/mm3); hypoglycaemia
(glucose <2.2 mmol/L); and spontaneous bleeding or
shock (systolic blood pressure <80 mmHg with cool ex-
tremities). Patients were excluded if they were <14 years
of age or if they had received parenteral anti-malarial
treatment for >48 hours before enrolment. Disease sever-
ity was defined by the number of these criteria that a pa-
tient satisfied. The independent prognostic utility of theadmission platelet count was compared with the widely
validated RCAM score [20-22] calculated from the patients’
respiratory rate and GCS on admission (Table 1). Major
bleeding was defined as bleeding which resulted in death or
necessitated blood transfusion.
On enrolment, a history was taken, a physical examin-
ation performed and venous blood collected. In Vietnam,
patients were randomized to receive intramuscular quin-
ine (n = 271) or intramuscular artemether (n = 279); all the
Bangladeshi and Indian patients received intravenous arte-
sunate. Patients received supportive care as per contem-
porary WHO treatment guidelines [11,23,24]. Access to
mechanical ventilation was limited in Vietnam; access to
both mechanical ventilation and renal replacement ther-
apy was limited in Bangladesh. Platelet transfusion was
not available at any of the sites. The peripheral parasite
count (parasites/μL) on admission was calculated from
the thin film using the formula: parasite count/1,000 red
blood cells × 125.6 × haematocrit (%); or from the thick
film using the formula: parasite count/200 white blood
cells × 40. In Vietnam haematological indices were manu-
ally determined in the hospital laboratory; in Bangladesh
and India they were measured with an automated analyser
in local private laboratories.
In Vietnam the hospital laboratory performed most bio-
chemical analysis, but plasma glucose and lactate were
measured on the ward using dedicated online analysers
(Analox, Middlesborough, United Kingdom). Biochemical
indices were measured in Bangladesh and India using
portable handheld analysers (i-Stat, Abbott, Princeton,
New Jersey, USA). Plasma was processed and stored at −80°
C for analysis of other laboratory parameters: plasma Plas-
modium falciparum histidine rich protein 2 (PfHRP2), a
measure of parasite biomass, was measured in Bangkok,
Thailand, using ELISA (Cellabs, Sydney, New South Wales,
Australia), according to the manufacturer’s instructions
with minor modifications [25]; angiopoietin-2 (Ang-2), a
measure of endothelial activation, was measured in Darwin,
Australia, using ELISA (R&D Systems, Minneapolis,
Minnesota, USA) [26].
In the Bangladeshi and Indian patients video recordings
of blood flow in the microcirculation were collected with
an orthogonal polarizing spectral (OPS) imaging device
(either Cytoscan from Cytometrics, Heathpark Honiton,
Devon, United Kingdom or Microscan from Microvision
Medical, Amsterdam, the Netherlands) and quantified
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Waltham, Massachusetts, USA) as described previously [17].
Statistics
Data were analysed using statistical software (Stata version
10, StataCorp, College Station, Texas, USA). Correlation
coefficients were determined using Spearman’s method.
Groups were analysed using the Kruskal-Wallis test and
the chi-squared test. Logistic regression was performed
where necessary and to control for any influence of the
study site or the administered anti-malarial therapy.
Ethics review
All of the studies received prospective ethical approval from
OXTREC (Oxford Tropical Research Ethics Committee)
and local ethics review bodies. The ethics and scientific-Table 2 Baseline characteristics of the patients
Variable n All (n = 647)
Age (years) 646 30 (22 to 42)
Sex (% male) 646 483 (75%)
Temperature (°C) 647 38.3 (37.5 to 39.0)
Mean arterial pressure (mmHg) 646 76.7 (70 to 86.7)
Heart rate (beats/minute) 641 106 (96 to 120)
Respiratory rate (breaths/minute) 642 28 (24 to 32)
Glasgow coma scale score 647 10 (8 to 15)
Haematocrit (%) 646 30 (24 to 36)
Reticulocyte count (%) 514 0.8 (0.4 to 1.2)
Reticulocyte index 517 0.5 (0.3 to 0.8)
White cell count (× 109/L) 643 8.7 (6.2 to 12)
Platelet count (× 109/L) 647 48 (30 to 72)
Mean platelet volume (fL) 34 11.4 (10.4 to 12.4)
Parasite count (parasites/mL) 639 90.4 (18.5 to 327.6)
Sequestration (% blocked capillaries) 107 13.3 (3.3 to 31.5)
PfHRP2 (ng/mL) 109 2,351 (1,198 to 4,805
Lactate (mmol/L) 640 3.5 (2.0 to 4.6)
Base deficit (mEq/L) 395 5 (2 to 10)
Anuric on admission 565 51/565 (9%)
Shock on admission 647 47/647 (7.3%)
Pulmonary oedema on admission 646 15/646 (2.3%)
Bleeding on admission 646 34/646 (5.2%)
Sodium (mmol/L) 460 133 (127 to 138)
Potassium (mmol/L) 525 4.0 (3.6 to 4.5)
Creatinine (μmol/L) 644 176 (123 to 282)
Total bilirubin (μmol/L) 544 57.8 (30.6 to 146.2)
Direct bilirubin (μmol/L) 420 27.2 (13.6 to 71.4)
Indirect bilirubin (μmol/L) 420 34.8 (17.0 to 74.8)
Angiopoietin-2 (ng/mL) 152 18.2 (10.2 to 29.8)
The values represent the median (interquartile range) and absolute number (%). PfHreview committee of The Center for Tropical Diseases in
Ho Chi Minh City approved the Vietnamese study, the
Bangladeshi Medical Research Council approved the
Bangladeshi studies and the institutional ethical board
of Ispat General Hospital approved the Indian studies.Results
Patients
Of the 560 Vietnamese patients, 538 (96.1%) had a platelet
count documented on admission. The 22 patients who did
not have a platelet count recorded had neither more severe
disease (P = 0.4), nor were more likely to die (P = 0.12). Of
the 142 Bangladeshi and Indian patients, 109 (76.8%) had
an admission platelet count recorded; 31 of the 33 patients
with a missing value were studied in 2004 and 2005 whenSurvived (n = 540) Died (n = 107) P
30 (22 to 40) 34 (26 to 45) 0.003
409 (76%) 74 (69%) 0.14
38.3 (37.5 to 39.0) 38 (37 to 39.0) 0.04
76.7 (70 to 86.7) 79.2 (66.9 to 90.0) 0.31
105 (95 to 120) 113 (100 to 123) 0.01
28 (24 to 32) 32 (28 to 40) <0.001
10 (8 to 15) 9 (7 to 13) <0.001
30 (24 to 36) 30 (23 to 36) 0.95
0.8 (0.4 to 1.2) 0.5 (0.3 to 1.1) 0.008
0.5 (0.3 to 0.9) 0.4 (0.2 to 0.7) 0.01
8.1 (6 to 11.2) 11.8 (9.1 to 16.3) <0.001
50 (34 to 78) 30 (22 to 52) <0.001
11.5 (10.4 to 12.4) 11.3 (11.2 to 12.6) 0.82
78.6 (16.1 to 326.7) 101.8 (33.3 to 373.3) 0.09
10 (2.9 to 26.6) 23.2 (10.0 to 44.0) 0.008
) 2,187 (976 to 4,216) 3,275 (1,479 to 6,406) 0.07
3.2 (2.0 to 4.6) 5.7 (3.4 to 9.0) <0.001
5 (2 to 8) 11 (7 to 17) <0.001
35/483 (7.3%) 16/82 (19.5%) <0.001
27/540 (5%) 20/107 (18.7%) <0.001
8/539 (1.5%) 7/107 (6.5%) 0.002
26/539 (4.8%) 8/107 (7.5%) 0.26
133 (127 to 138) 135 (130 to 140) 0.02
4.0 (3.5 to 4.5) 4.2 (3.7 to 4.8) 0.02
176 (123 to 254) 239 (146 to 441) <0.001
51 (27.2 to 119.0) 146.2 (52.7 to 248.2) <0.001
23.8 (13.6 to 64.6) 62.9 (20.4 to 127.6) <0.001
34 (14.4 to 64.6) 73.1 (40.4 to 102.3) <0.001
13.5 (9.4 to 25.1) 25 (14.8 to 41.0) <0.001
RP2: Plasmodium falciparum histidine rich protein 2.
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The two remaining Bangladeshi and Indian patients with-
out a documented platelet count (from 2011 and 2008
respectively) both survived.
The baseline characteristics of the 647 patients with a
platelet count recorded on admission are presented in
Table 2. Overall, 107 patients (16.5%) died before dis-
charge; the case-fatality rate was higher in the Bangla-
deshi and Indian patients than the Vietnamese patients
(30 out of 109 (27.5%) versus 77 out of 538 (14.3%);
odds ratio (OR) (95% confidence interval (CI)): 2.27
(1.40 to 3.69), P = 0.001), although the difference was
not significant when controlled for disease severity (OR
(95% CI): 1.46 (0.84 to 2.52), P = 0.18).
Most patients (614 out of 647, 94.9%) were thrombocy-
topenic (platelet count <150 × 109/L) on admission; 328
(50.7%) had a platelet count <50 × 109/L (Figure 1). The
mean platelet volume was only available in 34 patients but
was generally increased: median (IQR) 11.4 (10.4 to 12.4)
fL (normal range 7.2 to 11.7 fL).
Association with bleeding complications
Bleeding was present on admission in 20 out of 328 patients
(6.1%) with a platelet count of <50 × 109/L and 14 out of
319 patients (4.4%) with a count ≥50 × 109/L (P = 0.33).
Bleeding developed in a further 60 out of 328 patients
(18.3%) with an admission platelet count of <50 × 109/L
and 37 out of 319 patients (11.6%) with a count ≥50 × 109/
L (P = 0.02). Major bleeding was not common, occurring at
some point in the admission of 50 (7.7%) of the patients (30
deaths, 20 additional patients requiring blood transfusion).
Although the admission platelet count was lower in pa-
tients with major bleeding (median (IQR, range): 40 (28 to
60, 9 to 420) × 109/L) than in patients without major bleed-
ing (50 (30 to 75, 4 to 290) × 109/L; P = 0.02), it failed toFigure 1 The peripheral platelet count of the patients on admission
to hospital.identify either population reliably (Table 3). Patients dying
with bleeding complications rarely died from bleeding
alone; these patients also usually had multi-organ dysfunc-
tion and satisfied a median (IQR) of 3 (2 to 4) other WHO
severity criteria on admission. Similarly the patients with
bleeding that required blood transfusion were also fre-
quently anaemic on enrolment (median (IQR) haematocrit
26% (23 to 32%)); many would have required blood trans-
fusion even if bleeding had not supervened. Major bleeding
episodes were most commonly gastrointestinal in origin.
Proton pump inhibitor therapy was not available at the time
of the Vietnam study and acid suppression therapy was
administered rarely prior to hospitalisation at any of
the study sites.
Association with disease severity, parasite burden and
measures of endothelial function
The admission platelet count correlated inversely with dis-
ease severity (rs = −0.21, P <0.001) and the circulating para-
site count (rs = −0.29, P <0.001). Measures of sequestration
(OPS imaging data) and total parasite biomass (PfHRP2)
were only available in Bangladeshi and Indian patients;
however, both correlated inversely with the admission per-
ipheral platelet count (rs = −0.31, P = 0.001 and rs = −0.28,
P = 0.003, respectively). Admission plasma Ang-2 concen-
trations were available in 152 cases (92 Bangladeshi and 60
Vietnamese patients) and were markedly elevated (median
(IQR) 18.2 (10.3 to 29.8) ng/mL). However, an inverse cor-
relation between plasma Ang-2 concentrations and the
peripheral platelet count failed to reach statistical signifi-
cance (rs = −0.15, P = 0.059) (Table 4).
Association with outcome and independent prognostic
utility
The admission platelet count correlated with the risk of
death in both datasets. Overall, the median (IQR) plate-
let count in the patients who died was 30 (22 to 52) ×
109/L compared to 50 (34 to 78) × 109/L in survivors
(P = 0.0001) (Figure 2). The case-fatality rate increased
with declining platelet count (Table 3): 77 out of 328 pa-
tients (23%) with severe thrombocytopenia (<50 × 109/L)
died (OR (95% CI): 2.96 (1.88 to 4.66), although when con-
sidered with other laboratory indices of disease severity,
severe thrombocytopenia was not independently predictive
of outcome (Table 5). Of the 39 patients with profound
thrombocytopenia (<20 × 109/L), 18 (46%) died (OR: 5.00
(95% CI 2.56 to 9.75). However, these patients were usually
relatively easy to identify: the median (IQR) GCS of these
39 patients was 8 (6 to 12) and the median (IQR) re-
spiratory rate was 33 (26 to 44) breaths per minute. The 18
patients with profound thrombocytopenia on admission
who later died concurrently satisfied a median (IQR) of 3
(3 to 4) WHO severity criteria and had pronounced de-
rangement of other laboratory indices (median (IQR) plasma
Table 3 Association between the admission platelet count, bleeding complications and outcome
Platelet count on admission
(× 109/L)
n Any bleeding during
hospitalisation
Died with bleeding
complications
Survived but required blood
transfusion for bleeding
Major bleedinga Died from
any cause
Less than 20 39 6 (15%) 0 3 (7.7%) 3 (7.7%) 18 (46%)
20 to 49 289 74 (26%) 20 (6.9%) 9 (3.1%) 29 (10 %) 59 (20%)
50 to 99 235 46 (20%) 9 (3.8%) 6 (2.6%) 15 (6.4%) 24 (10%)
≥100 84 5 (6%) 1 (1.2%) 2 (2.4%) 3 (3.6%) 6 (7.1%)
Total 647 131(20%) 30 (4.6%) 20 (3.1%) 50 (7.7%) 107 (17%)
a Patients who died from bleeding complications or who had bleeding and received blood transfusion.
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mEq/L; plasma creatinine, 229 (140 to 453) μmol/L;
and total bilirubin, 195 (105 to 260) μmol/L).
In total, 642 patients (99.2%) had data allowing retro-
spective calculation of a RCAM score on admission; 104
of these patients died, 93 (89.4%) of whom had a RCAM
score ≥2. The platelet count did not improve the identifi-
cation of the 11 patients who died but were classified as
low-risk by the RCAM score (RCAM score <2). The plate-
let counts of these 11 patients (median (IQR, range): 40
(30 to 60, 24 to 98) × 109/L)) were not statistically or clin-
ically significantly different to the 151 patients with anTable 4 Association between the platelet count and clinical a
Variable Platelets ≥ 50 × 109/L n
Died 30/319 (9.4%)
Age (years) 28 (22 to 38)
Sex (% male) 237/319 (74.0%)
Temperature (°C) 38.5 (37.5 to 39.0)
Mean arterial pressure (mmHg) 76.7 (70.0 to 86.7)
Heart rate (beats/minute) 100 (96 to 120)
Respiratory rate (breaths/minute) 28 (24 to 32)
Glasgow Coma Scale Score 10 (8 to 15)
Haematocrit (%) 28 (23 to 35)
White cell count (× 109/L) 8.8 (6.3 to 11.6)
Reticulocyte count (%) 0.9 (0.5 to 1.5)
Parasite count (parasites/mL) 42.2 (10.4 to 184.3)
Sequestration (% blocked capillaries) 6.6 (1.7 to 18.3)
PfHRP2 (ng/mL) 1,739 (783 to 3,203)
Lactate (mmol/L) 2.9 (1.9 to 4.4)
Base deficit (mEq/L) 4 (1 to 8)
Creatinine (μmol/L) 164 (115 to 264)
Total bilirubin (μmol/L) 44.2 (23.8 to 115.6)
Indirect bilirubin (μmol/L) 26.5 (13.6 to 54.4)
Angiopoietin-2 (ng/mL) 16.3 (9.4 to 30.2)
Anuric on admission 20/289 (6.9%)
Shock on admission 19/319 (6.0%)
Pulmonary oedema on admission 6/319 (1.9%)
The values represented the median (interquartile range) and absolute number (%).RCAM score <2 who survived: 48 (32 to 78, 8 to 272) ×
109/L) (P = 0.56) (Figure 3). Of the patients with profound
thrombocytopenia (<20 × 109/L), 34 out of 39 (87.2%) had
a RCAM score ≥2; the five patients with profound
thrombocytopenia but a RCAM score <2 all survived.
Discussion
In this multi-centre study of adults with severe falcip-
arum malaria, the platelet count on admission correlated
with disease severity and outcome, but had limited inde-
pendent prognostic utility when considered with other la-
boratory indices. Knowledge of the platelet count offerednd other laboratory indices on admission
= 319 Platelets <50 × 109/L n = 328 P
77/328 (23.5%) <0.001
33 (24 to 45) <0.001
246/327 (75.2%) 0.79
38.1 (37.5 to 39.2) 0.74
78.3 (70.0 to 90.0) 0.05
110 (95 to 120) 0.09
28 (24 to 36) 0.006
11 (8 to 15) 0.11
31 (25 to 38) <0.001
8.6 (6.1 to 12.6) 0.75
0.6 (0.3 to 1.0) <0.001
151.6 (32.3 to 479.9) <0.001
16.6 (6.6 to 34.9) 0.01
2,834 (1,482 to 5,209) 0.01
4.0 (2.4 to 6.3) <0.001
6 (3 to 11) <0.001
185 (138 to 310) 0.007
74.8 (40.8 to 170.0) <0.001
47.6 (23.8 to 85.0) <0.001
19.4 (11.6 to 29.8) 0.14
31/276 (11.2%) 0.07
28/328 (8.5%) 0.21
9/327 (2.8%) 0.46
PfHRP2: Plasmodium falciparum histidine rich protein 2.
Figure 2 The relationship between the platelet count on admission
and outcome.
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the respiratory rate and GCS. The platelet count on ad-
mission was lower in patients who went on to develop
major bleeding, but was unable to identify this population
reliably.
Thrombocytopenia was more frequent in this series
than in previous studies of adults with falciparum malaria
[2,3,27], presumably as a result of a strict case definition
leading to the enrolment of patients with more severe
disease. The increased mean platelet volume, although
available in few patients, suggests the presence of young,Table 5 Independent ability of laboratory variables measured
Variable Cut-off Numbera
White cell count >11 × 109/L 195 (30%)
Plasma creatinine >265 μmol/L 176 (27%)
Plasma lactate >4 mmol/L 260 (41%)
Total bilirubin >51 μmol/L 313 (57%)
Platelet count <50 × 109/L 328 (51%)
Reticulocyte count <0.5% 190 (37%)
aNumber (%) of patients with a value meeting the cut-off. The denominator for the
a measurement available (not all patients had data for every variable). Multivariable
chosen on the basis of a significant association with outcome in univariate analysis
chosen based on the WHO severity criteria cut-off (for those that are WHO severity
criteria, the cut-offs were based on the reference range (white blood cell count and
included in the model as there were fewer data for this variable; acidosis was reprefunctional platelets, and likely explains the relatively low
incidence of major bleeding - despite the profound
thrombocytopenia - seen in the study. This low incidence
of major bleeding and the significant challenges associated
with the delivery of blood products in the resource-poor
setting [28] argues strongly against the routine use of
platelet transfusions in these patients. The prompt and
spontaneous recovery seen in the platelet counts of this
patient population provides additional support for this
clinical approach [29].
After an association between thrombocytopenia and out-
come was demonstrated in a large Indonesian population-
based study of malaria, it was suggested that a platelet
count of less than 20 × 109/L should be used as a severity
criterion in malaria and that the platelet count might have
use in patient triage [12]. An Indian hospital-based study
reached similar conclusions [13]. A platelet count has the
virtue of being easier to measure than some other recog-
nized laboratory predictors of mortality, such as plasma
lactate and base deficit. Our series confirms that profound
thrombocytopenia should alert clinicians managing pa-
tients with malaria - patients with a platelet count below
20 × 109/L were five times more likely to die than patients
with a higher platelet count. However, if clinicians in this
series had used the platelet count to triage patients, it
would not have resulted in significant changes in their
management. None of the patients who would later die
despite being classified as low-risk with the simple bedside
RCAM score had an admission platelet count below 20 ×
109/L. Thus, whilst there is an association between the
presence of profound thrombocytopenia and the likelihood
of a complicated course, the addition of another severity
criterion to the already complex definition of severe falcip-
arum malaria [30] may not assist clinicians substantially.
OPS imaging has been used to demonstrate microvascu-
lar obstruction in vivo in adults with falciparum malaria
[15]. The correlation seen in this series between micro-
vascular obstruction and the circulating platelet count may
represent the diffuse sequestration of radiolabelled plateletson admission to predict outcome
Odds ratio 95% Confidence interval P
2.74 1.53 to 4.89 0.001
2.40 1.3 to 4.43 0.005
2.25 1.26 to 4.02 0.006
2.26 1.13 to 4.50 0.02
1.75 0.96 to 3.18 0.07
1.19 0.63 to 2.26 0.59
calculation of the percentage was the number of patients in the dataset with
logistic regression with death as the dependent variable; explanatory variables
(with P <0.01 allowing for multiple comparisons, see Table 2). The cut-offs were
criteria: creatinine, lactate and bilirubin). For those that are not WHO severity
reticulocyte count) and previous studies (platelet count). Base deficit was not
sented by plasma lactate.
Figure 3 Ability of the platelet count on admission to predict outcome when compared the simple RCAM score. *In five patients the
respiratory rate on admission was not recorded. IQR, interquartile range.
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[5]. Certainly platelets have been implicated in the patho-
genesis of two of the processes (auto-agglutination [31]
and cytoadherence [32]) that contribute to microvascular
obstruction, and increased numbers of platelets and platelet-
fibrin thrombi have been reported in the cerebral microcir-
culation of paediatric cases of fatal falciparum malaria [8].
However, platelets are notable by their absence from the
microcirculation in adult post-mortem series [33,34]. Fur-
thermore thrombocytopenia is also frequent in Plasmodium
vivax malaria [12,27], a disease in which significant seques-
tration is absent [35]. Although severe thrombocytopenia is
less frequent in vivax malaria, there are many shared find-
ings, including increased mean platelet volumes and a cor-
relation with the circulating parasite count [36], suggesting
that there are common pathways in the pathogenesis of the
thrombocytopenia in the two infections.
One of these common pathways is likely to be endothe-
lial activation [34,37]. During endothelial activation, acti-
vated high-multimeric von Willebrand Factor (vWF) is
released from specialized secretory vesicles in endothelial
cells known as Weibel-Palade bodies (WPBs) [38]. Once
in the circulation, vWF aggregates platelets, resulting in
their clearance from the circulation. Studies performed in
both falciparum and vivax malaria demonstrate an inverseassociation between the circulating platelet count and
plasma concentrations and activity of vWF [9,10]. Falls in
the plasma concentrations of ADAMTS13, a regulating
enzyme that catabolizes vWF multimers, are also seen in
infections with both species [9,10]. Although vWF and
ADAMTS13 were not determined in this series, plasma
concentrations of Ang-2 were markedly elevated, suggest-
ing the presence of pronounced systemic endothelial acti-
vation. Indeed, Ang-2 is stored in WPBs and is released
with vWF during WPB exocytosis.
An interaction between microvascular obstruction and
endothelial activation may explain the association between
the OPS findings and the circulating platelet count seen in
this series [34]. The resting, un-activated endothelium
constitutively releases nitric oxide, which helps maintain
endothelial quiescence and also directly inhibits platelet
aggregation [39,40]. The shear stress of normally flowing
blood is the principal signal for this nitric oxide release
[40] and it would therefore be expected that microvascular
obstruction could lead to endothelial activation via this
mechanism. Microvascular obstruction also leads to tissue
hypoperfusion and hypoxia - another potent stimulus for
endothelial activation. Endothelial activation facilitates
further cytoadherence through the upregulation of endothe-
lial receptors that act as ligands for parasitized erythrocytes
Hanson et al. BMC Medicine  (2015) 13:97 Page 8 of 9[34], resulting in further microvascular obstruction and
potentially precipitating a vicious cycle.
The study has other noteworthy haematological find-
ings. Erythropoiesis was significantly depressed with a
reticulocyte production index of less than 1 in almost
90% of the patients. Accordingly, most patients were an-
aemic but severe anaemia (haematocrit <20%) was rela-
tively infrequent, a finding that may reflect the fact that
this study was performed exclusively in adults [41]. It
suggests that prognostic tools that use the platelet count
and haemoglobin concentration may have limited utility
in the adult population [12]. The median white blood
cell count was greater in this cohort than in outpatients
with malaria in whom mild leucopenia is typical [42].
The admission white cell count was significantly higher
in the patients who died than in survivors, an association
that has been recognized previously [13,43].
Our study had significant limitations. Its retrospective de-
sign precluded complete data collection. Measurements of
vWF and ADAMTS13 concentrations and activity would
have defined the extent of this pathway’s contribution to
the pathogenesis of thrombocytopenia. Coagulation studies
would have defined the contribution of coagulopathy to
bleeding complications, although disseminated intravascu-
lar coagulation was rarely suspected clinically. The study
assessed the prognostic utility of the admission platelet
count, but sequential measurement may have improved
its ability to predict bleeding complications, in particular.
The dataset consisted of patients who had already satisfied
a definition of severe malaria; the prognostic utility of the
platelet count may be different outside of a study setting.
Because the studies only enrolled adults, the findings
cannot necessarily be generalized to children.Conclusions
Adults with severe falciparum malaria are usually thrombo-
cytopenic, some profoundly so. Despite this, the risk of
major bleeding is relatively low. Patients with multi-organ
involvement and those who will die before discharge are
more likely to have a lower platelet count; however, these
patients are more reliably identified by simple clinical assess-
ment and traditional laboratory indices of severe disease.Competing interests
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